Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of PRX-102 in Adult Fabry Patients
NCT01981720Phase 2Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Jan 2014
- Primary completion
- Aug 2020
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Primary endpoint: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 at 60 months. Started Jan 2014; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01981720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981720.